Jonathan Zalevsky, Chief R&D Officer at NEKTAR THERAPEUTICS (NKTR), sold 5,681 shares at $70.00 ($398K) on 2026-06-30, disclosed to the SEC on 2026-07-02.
Scheduled sale ($398k) by Chief R&D Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| NKTR | SELL | 2026-05-21 | $13K | — | Filing → |
| NKTR | SELL | 2026-02-20 | $13K | — | Filing → |
| NKTR | SELL | 2026-01-22 | $138K | — | Filing → |